Company Profile

Shandong Yikang Pharmaceutical Co., Ltd. specializes in the research, production, and marketing of chemical active pharmaceutical ingredients (APIs), as well as providing comprehensive CDMO services for a wide range of APIs and pharmaceutical intermediates. Established in March 2019 with a registered capital of RMB 3 million, the company has planned a facility covering an area of 200,000 square meters, divided into three construction stages. The first phase, spanning approximately 50,000 square meters, commenced construction in February 2020, with its main structural components already completed. This initial phase is projected to finish by June 2023 and become operational in July. Currently, Yikang produces key API products including febuxostat, rosuvastatin calcium, lenvatinib mesylate, sunitinib malate, sorafenib tosylate, and erlotinib hydrochloride.